CurveBeam AI Shares Rally 6.25%, Still Trade Below Placement Price

CurveBeam AI Ltd (ASX: CVB) shares climbed 6.25% to AUD 0.017 (roughly USD 0.011) in the latest session, valuing the orthopedic imaging company at about AUD 8.23 million on turnover of just AUD 16,956. The stock remains 75.71% lower than where it traded a year ago.

The bounce lands days after CurveBeam priced fresh shares at 2 cents apiece for an institutional placement, a level this week’s gain still hasn’t reached. That gap between the placement price and the trading price sits at the center of what is actually a mixed quarter: receipts are rising, a robotic-surgery validation is nearing completion, and a China regulatory decision is due within months, even as the company leans on director loans and a follow-on retail offer to keep the lights on.

A 6.25% Bounce on AUD 16,956 of Turnover

Turnover of AUD 16,956 at a 1.7 cent share price works out to roughly 1 million shares changing hands, a thin volume even by the standards of a stock this small. CurveBeam AI develops and sells point-of-care CT scanners that image patients standing upright rather than lying flat, alongside AI-enabled software for reading those scans.

The company sits inside a broader wave of investor interest in healthcare artificial intelligence, part of a wider shift across the tech sector from AI capability races to counting the actual token bills that come with running these systems. Hospitals and imaging providers are still buying, but CurveBeam’s own numbers show how slowly that buying converts into cash.

The Placement Priced Below Today’s Rally

CurveBeam AI secured binding commitments for an AUD 5 million institutional and related party placement at AUD 0.02 per share, a price representing an 11.1% premium to the July 3 closing price. Directors Greg Brown and Arun Singh together subscribed for AUD 2.4 million of that raise.

Singh separately advanced the company an unsecured loan on commercial terms, keeping trading running while the placement completed. Alongside the institutional raise, a Share Purchase Plan is open to eligible shareholders in Australia and New Zealand, capped at AUD 100,000 per applicant.

A separate Appendix 3B lodged with the ASX covers up to 111,111,111 new shares, with acceptances scheduled to close on August 21, 2026 and issue expected on August 28. Net proceeds from the raise are earmarked for sales, research and supply chain work, with particular focus on readying the HiRise system for launch in China.

Receipts Jump 80 Percent While the Backlog Shrinks

CurveBeam generated AUD 2.58 million in customer receipts during the fourth quarter of its 2026 financial year, up 80% from AUD 1.43 million in the prior quarter. The company ended that quarter, which closed June 30, with AUD 1.64 million in cash, before the placement lifted its pro forma balance to AUD 6.64 million.

The backlog moved the other way. CurveBeam carried AUD 4.2 million of purchase orders and receivables into the new financial year, down 12.5% from the AUD 4.8 million it carried into the prior quarter. Management has said revenue recognition typically takes two to six months from the date of a purchase order, meaning today’s backlog shrinkage will show up in receipts later this year.

Separately, the company has submitted matched HiRise and multidetector CT patient scans to a robotics surgery vendor for validation, with the images meeting or exceeding the control metrics used for comparison. CurveBeam is awaiting the vendor’s final review.

In my opinion, weight bearing CT will be the standard of care for all foot and ankle injuries. For all foot and ankle pathology because we walk on our feet.

Dr. Hodges Davis, an orthopedic surgeon at OrthoCarolina, made that case in comments shared through CurveBeam’s own channels. Weight-bearing CT has become a routine part of his practice for fracture assessment and fusion evaluation, the kind of clinical habit CurveBeam is counting on to spread to other surgeons.

What Does CurveBeam AI Actually Sell?

CurveBeam AI makes a family of cone-beam CT scanners built around one idea: imaging the foot, ankle, knee, hip or wrist while the patient bears weight on it, not lying supine. The lineup ranges from the original foot-and-ankle scanner to a full lower-body system, backed by AI software that measures bone alignment automatically.

• HiRise – bilateral, weight-bearing CT imaging covering the entire lower extremities, hips, pelvis and distal upper extremities.
• LineUP – bilateral, weight-bearing CT imaging of the knees and distal lower and upper extremities.
• pedCAT and pedCAT Premium – the original foot and ankle system, introduced in 2012 as the first CT scanner offering true bilateral weight-bearing imaging.
• InReach – point-of-care extremity CT for the upper extremities and non-weight-bearing lower extremities.
• CubeVue Autometrics – AI software that automatically segments foot and ankle scans for measurement.

CurveBeam has installed more than 160 of these systems at orthopedic institutions worldwide, and its patent portfolio runs to 37 granted patents and 27 pending. The business employs more than 70 people, with its corporate office, AI development and intellectual property functions based in Melbourne and its global operations headquarters in Hatfield, Pennsylvania.

China’s Approval Clock Keeps Ticking

CurveBeam has submitted its responses to feedback from China’s National Medical Products Administration on the HiRise application and continues to expect clearance in the second half of 2026, with the company’s own investor materials pointing to the fourth quarter specifically. A partnership with Wego Orthopedics is meant to give CurveBeam local manufacturing and distribution muscle once that approval lands.

None of it is locked in yet. Here’s where the picture splits between what’s confirmed and what still depends on decisions outside the company’s control.

• Where the numbers are firm: AUD 2.58 million in Q4 receipts, an AUD 5 million placement with binding commitments, and a director loan already advanced to cover working capital.
• Where it’s still open: whether NMPA grants clearance on the company’s own second-half timeline, whether the Share Purchase Plan reaches its AUD 1 million target, and whether the shrinking order backlog rebuilds fast enough to keep receipts climbing next quarter.

A Hold Rating Sits Far Above the Trading Price

The most recent analyst rating tracked on CurveBeam AI is a Hold with an AUD 0.15 price target, more than eight times the stock’s latest trading level. Stockopedia’s quantitative screen, meanwhile, classifies the stock a Value Trap, the label its model reserves for shares that look statistically cheap but score poorly on underlying quality.

Both views can be true at once. CurveBeam’s balance sheet still leans on director loans and a follow-on share offer to bridge the gap until NMPA clearance and new orders arrive, even as the analyst target implies room to run once China opens up.

Small medical technology stocks swing hard for exactly this reason: a handful of milestones, a single regulatory letter, or one large purchase order can move the valuation more than any single trading session does. It’s a pattern that echoes the swings that have sent AI chip stocks swinging across the region this year, where sentiment moves faster than the underlying business.

Frequently Asked Questions

What Does CurveBeam AI Make?

CurveBeam AI builds point-of-care CT scanners that image patients standing upright, plus AI software that reads those scans for orthopedic surgeons. Beyond its ASX listing, US investors can also access the stock over the counter under the ticker CRVAF.

How Many Shares Actually Traded in the Rally?

Turnover of AUD 16,956 divided by the AUD 0.017 share price works out to roughly 1 million shares changing hands, a volume thin enough that a handful of trades can move the price several percent in either direction.

Is CurveBeam’s HiRise Scanner Cleared for Sale Everywhere?

Not yet everywhere. HiRise already carries FDA clearance in the United States along with TGA approval in Australia and CE marking in Europe, but clearance from China’s National Medical Products Administration remains pending, expected in the second half of 2026.

What Will CurveBeam Do With the Placement Money?

Net proceeds are earmarked for sales and marketing, research and development, and supply chain activities, with particular focus on preparing the HiRise system for its China market launch.

Who Competes With CurveBeam AI?

CurveBeam’s named competitors include MARS Bioimaging, Adiposs and RAYDIAX. RAYDIAX, the most recently funded of the group, secured 5.86 million US dollars in March 2026, a sign competitors are also racing to fund their own imaging platforms.

Disclaimer: This article is for general informational purposes only and does not constitute financial, investment or legal advice. CurveBeam AI Ltd is a small capitalisation stock and any investment in it carries elevated, speculative risk, including the risk of substantial loss. Readers should consult a licensed financial adviser before making investment decisions. Figures cited are accurate as of the date of publication and may change without notice.